Evidence map›Paper›PMID 41980974›Full record

ArticleNPJ vaccines2026

Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.

Vincent Dussupt, Jaime L Jensen, Angélica Peña Rosado, Marissa Donofrio, Jill Pflugheber, Letzibeth Mendez-Rivera, Rajeshwer S Sankhala, Wei-Hung Chen, Bonnie M Slike, Annika Schmid and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Vincent DussuptViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Jaime L JensenViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Angélica Peña RosadoMicrobiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
Marissa DonofrioMicrobiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
Jill PflugheberMicrobiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
Letzibeth Mendez-RiveraU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Rajeshwer S SankhalaViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Wei-Hung ChenViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Bonnie M SlikeU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Annika SchmidU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Ursula TranU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Lily MetzgerU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Caroline E PetersonViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Amelia K PintoMicrobiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
Sandhya VasanU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Natalie D CollinsViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Aaron FarmerViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nelson L MichaelCenter for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
M Gordon JoyceViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
James D BrienMicrobiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA.
Shelly J KrebsViral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA. skrebs@hivresearch.org.

Funding

National Institute of Allergy and Infectious Diseases R01AI155983National Institute of infectious R01AI155983
6 · The paper itself

Abstract

Zika virus (ZIKV) vaccine candidates developed through Phase I clinical trials are based on the full-length envelope glycoprotein (E), which presents both desirable and undesirable antigenic determinants. Among the latter, the conserved fusion loop epitope (FLE) within domain II is a major target for flavivirus cross-reactive and poorly neutralizing responses. To eliminate unwanted FLE targeting, we redesigned ZIKV E using a reverse vaccinology approach, excising domain II and allowing domains I and III (DI-DIII) to fold into an independent subunit harboring key neutralizing epitopes. Ifnar1

Identifiers

PMID41980974
PMCPMC13270120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.